Previous Article | Next Article ![]()
Journal of Clinical Microbiology, August 2001, p. 2937-2945, Vol. 39, No. 8
Roche Molecular Systems, Inc., Pleasanton,
California 94588,1 and Roche
Diagnostics, K. K., Tokyo, Japan2
Received 10 April 2001/Returned for modification 16 May
2001/Accepted 11 June 2001
We have developed an automated multiplex system for simultaneously
screening hepatitis B virus (HBV), hepatitis C virus (HCV), and human
immunodeficiency virus type 1 (HIV-1) in blood donations. The assay,
designated AMPLINAT MPX HBV/HCV/HIV-1 Test (AMPLINAT MPX), consists of
virus extraction and target sequence-specific probe capture on specimen
preparation workstation GT-X (Roche Diagnostics K.K., Tokyo, Japan) and
amplification and detection by TaqMan PCR on the ABI PRISM 7700 Analyzer (Perkin-Elmer Applied Biosystems, Foster City, Calif.). An
internal control (IC) is incorporated in the assay to monitor the
extraction, target amplification, and detection processes. The assay
yields qualitative results without discrimination of the three targets.
Detection limits (95% confidence interval) are 22 to 60 copies/ml for
HBV, 61 to 112 IU/ml for HCV, and 33 to 66 copies/ml for HIV-1, using a
specimen input volume of 0.2 ml. The AMPLINAT MPX assay detects a broad range of genotypes or subtypes for all three viruses and has a specificity of 99.6% for all three viruses with seronegative
specimens. In an evaluation of seroconversion panels, the AMPLINAT MPX
assay detects HBV infection an average of 24 days before the detection of HBsAg by enzyme immunoassay. HCV RNA was detected an average of 31 days before HCV antibody. HIV-1 RNA was detected an average of 14 days
before HIV-1 antibody and an average of 9 days before p24 antigen. The
Japanese Red Cross has been evaluating the AMPLINAT MPX system since
October 1999. The clinical performance indicates that the AMPLINAT MPX
system is robust, sensitive, and reproducible, with a high percentage
of valid assay runs (96.8%), a low false-positive rate (0.34%), and a
low IC failure rate (0.24%).
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.8.2937-2945.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Automated Multiplex Assay System for Simultaneous Detection of
Hepatitis B Virus DNA, Hepatitis C Virus RNA, and Human
Immunodeficiency Virus Type 1 RNA
*
Corresponding author. Mailing address: Roche Molecular
Systems, Inc., 4300 Hacienda Dr., Pleasanton, CA 94588. Phone: (925) 730-8150. Fax: (925) 225-0760. E-mail: qi.meng{at}roche.com.
Present address: Applera, Inc., Alameda, Calif.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|